Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

89.50CHF
24 Mar 2017
Change (% chg)

CHF1.80 (+2.05%)
Prev Close
CHF87.70
Open
CHF88.00
Day's High
CHF89.90
Day's Low
CHF87.70
Volume
100,791
Avg. Vol
67,489
52-wk High
CHF95.35
52-wk Low
CHF61.20

BSLN.S

Chart for BSLN.S

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.47
Market Cap(Mil.): CHF1,057.68
Shares Outstanding(Mil.): 11.82
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -5.07 -- --
ROI: -17.54 -2.56 13.01
ROE: -- 5.14 14.16

BRIEF-Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million

* In 2017, Basilea will further advance clinical development of its oncology drug candidates and expects to complete dose-escalation in bal101553's phase 1/2a studies and bal 3833's phase 1 study

Feb 20 2017

BRIEF-Basilea antifungal Cresemba (isavuconazole) launched in France

* Says basilea's antifungal cresemba (isavuconazole) launched in france Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Nov 15 2016

More From Around the Web

Earnings vs. Estimates